Literature DB >> 18838928

Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease.

Kristin P Barton1, Ricardo Munoz, Victor O Morell, Constantinos Chrysostomou.   

Abstract

OBJECTIVE: In this report, we describe the use of dexmedetomidine as the primary sedative agent while performing invasive procedures in infants and toddlers with congenital heart disease who are breathing spontaneously.
DESIGN: Retrospective case review.
SETTING: University Hospital, pediatric cardiac intensive care unit. PATIENTS: Six spontaneously breathing children, five infants and one toddler, all with congenital heart disease, who received dexmedetomidine as the primary sedative agent while undergoing an invasive procedure.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Six patients with congenital heart disease, age 3 days-29 months were included. Five of the patients were <6 months of age. Each patient underwent an invasive procedure including central venous line placement, chest tube insertion, fiberoptic bronchoscopy, and femoral cut-down for Broviac placement. All patients were breathing spontaneously throughout their procedure. Dexmedetomidine was used as the primary sedative agent during the procedure with additional sedation provided with low dose ketamine for patient movement in three of the six patients. The average dexmedetomidine dose used was 1.5 microg/kg (1-3 microg/kg). An additional low dose of ketamine, 0.7 mg/kg (0.3-1.5 mg/kg), was used in 50% of the patients. All patients breathed spontaneously without significant desaturation throughout the procedure, and although there was a trend toward lower blood pressure and heart rate, all patients remained warm and well perfused. Each of the six procedures was successfully completed without any associated complications.
CONCLUSIONS: Our experience suggests that invasive procedures can be successfully performed in spontaneously breathing infants and toddlers with congenital heart disease using dexmedetomidine alone or in combination with low dose ketamine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838928     DOI: 10.1097/PCC.0b013e31818d320d

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  24 in total

1.  Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease.

Authors:  Nelson H Burbano; Andrea V Otero; Donald E Berry; Richard A Orr; Ricardo A Munoz
Journal:  Intensive Care Med       Date:  2011-12-13       Impact factor: 17.440

Review 2.  Anesthesia for Advanced Bronchoscopic Procedures: State-of-the-Art Review.

Authors:  Basavana G Goudra; Preet Mohinder Singh; Anuradha Borle; Nahla Farid; Kassem Harris
Journal:  Lung       Date:  2015-04-29       Impact factor: 2.584

3.  Dexmedetomidine in current anaesthesia practice- a review.

Authors:  Shagufta Naaz; Erum Ozair
Journal:  J Clin Diagn Res       Date:  2014-10-20

4.  Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization.

Authors:  E H Jooste; W T Muhly; J W Ibinson; T Suresh; D Damian; A Phadke; P Callahan; S Miller; B Feingold; S E Lichtenstein; J G Cain; C Chrysostomou; P J Davis
Journal:  Anesth Analg       Date:  2010-11-08       Impact factor: 5.108

5.  Electrocardiographic effects of dexmedetomidine in patients with congenital heart disease.

Authors:  Constantinos Chrysostomou; Rukmini Komarlu; Steven Lichtenstein; Dana Shiderly; Gaurav Arora; Richard Orr; Peter D Wearden; Victor O Morell; Ricardo Munoz; Edmund H Jooste
Journal:  Intensive Care Med       Date:  2010-03-06       Impact factor: 17.440

Review 6.  Pain management in newborns.

Authors:  Richard W Hall; Kanwaljeet J S Anand
Journal:  Clin Perinatol       Date:  2014-10-07       Impact factor: 3.430

7.  A high dose of dexmedetomidine using the BIS monitor™ for diagnostic and interventional cardiac catheterization in a toddler with congenital heart disease.

Authors:  Takayuki Kunisawa; Atsushi Kurosawa; Mitsuteru Oikawa; Masahiro Mizobuchi; Dai Hayashi; Hiroshi Iwasaki
Journal:  J Anesth       Date:  2011-12-25       Impact factor: 2.078

Review 8.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

9.  Extended infusion of dexmedetomidine to an infant at sixty times the intended rate.

Authors:  Bryan A Max; Keira P Mason
Journal:  Int J Pediatr       Date:  2010-09-08

10.  The hemodynamic response to dexmedetomidine loading dose in children with and without pulmonary hypertension.

Authors:  Robert H Friesen; Christopher S Nichols; Mark D Twite; Kathryn A Cardwell; Zhaoxing Pan; Biagio Pietra; Shelley D Miyamoto; Scott R Auerbach; Jeffrey R Darst; D Dunbar Ivy
Journal:  Anesth Analg       Date:  2013-08-19       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.